Circulating Tumor DNA in Patients With Colorectal Cancer Undergoing Curative-intent Surgery for Liver Metastases: Prospective, Multicenter, GERCOR Cohort
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.
⁃ The patient will be included if:
• Has signed informed consent form and is willing to comply with all study procedures and availability for the study duration,
• Is ≥ 18 years of age,
• Has histologically confirmed colorectal adenocarcinoma,
• Has resected primary tumor or is eligible to primary tumor and CRLM (in case of synchronous metastases) resection within 6 months prior to study inclusion,
• Has isolated CRLM that is deemed resectable or potentially resectable (extrahepatic metastases excluded, except infracentimetric non-specific lung lesions with largest diameter \<1 cm and maximal number of ≤3) as judged by a multidisciplinary team meeting (based on CT scans of chest, abdomen, and pelvis \[or MRI if CT not possible\]),
• Is eligible to surgical procedure,
• Is fit for the chemotherapy-surgery combination treatment,
• Is registered in a national health care system (Protection Universelle Maladie \[PUMa\] included).